Back to Evidence

An AI Tool for Doctors to Review Ganmaoling Granules Efficacy and Safety Evidence | QSevidence 2026

Evidence-Based Medicine21 min read

Evaluating a cold medicine means asking more than whether symptoms improve.

An AI Tool for Doctors to Review Ganmaoling Granules Efficacy and Safety Evidence | QSevidence 2026

Clinicians need to understand the population, comparator, timing and potential harms behind that improvement. In this AI tool for doctors use case, QSevidence supports retrieval, evidence comparison and source tracing for research on 999 Ganmaoling granules. It helps physicians, pharmacists and researchers organize product information and clinical evidence for professional review.

Research summary: a verifiable efficacy and safety question

The proposed systematic review concerns patients with the common cold receiving an explicitly identified granule formulation, compared with placebo, usual management or another symptomatic medicine. Outcomes include symptom relief, recovery and adverse events. Monotherapy and add-on treatment require separate comparisons. This article presents an evaluation framework, not a completed quantitative synthesis: trial counts, pooled effects and adverse-event proportions require identifiable primary reports and reproducible extraction before publication.

Define the illness and the population first

Congestion, runny nose, sore throat, headache and fever can occur together without identifying a single disease. CDC describes the common cold as a viral upper respiratory infection and distinguishes influenza and COVID-19, which may produce similar symptoms. Eligibility should therefore document diagnostic criteria, illness duration and competing respiratory diagnoses. CDC: About Common Cold.

Adults and children, outpatients and hospitalized patients, and treatment-naive and previously treated participants should be characterized separately. Baseline severity, chronic conditions and time from onset to first treatment may affect recovery. If traditional Chinese medicine syndromes are included, record their diagnostic criteria and assessors rather than equating all common colds with one syndrome. Clinical disease definitions and syndrome classifications should remain distinct fields.

Product identity comes before a forest plot

For every trial, record the generic and trade names, manufacturer, approval information, dosage form, strength, study regimen and applicable label. Ganmaoling granules, compound Ganmaoling preparations, capsules and pediatric products require individual identification. Similar names alone provide an inadequate basis for pooling interventions.

China Resources Sanjiu describes Ganmaoling granules as a combined Chinese and Western medicine and cautions against simultaneous use with similar cold medicines. Its service information offers product-identification and medication-checking leads, rather than randomized comparative evidence. Current product-specific requirements should be checked against the applicable label with professional review. China Resources Sanjiu: product service information.

Translate the protocol into an extraction structure

DomainFields to extractInterpretive purpose
ParticipantsAge, diagnosis, illness duration, severity and comorbiditiesEstablish applicability and comparable recovery starting points
InterventionProduct identity, duration, background care and rescue medicationSeparate monotherapy from incremental add-on effects
SymptomsOutcome definitions, instruments and assessment timesCompare outcomes with matching clinical meaning
Study qualityAllocation, concealment, blinding, attrition and prespecified outcomesAssess potential distortion of effect estimates
HarmsEvent type, severity, ascertainment, follow-up and denominatorsDistinguish active monitoring, spontaneous reports and missing reporting

A search can combine Chinese and English drug names, brand variants, common-cold terminology and randomized-trial terms across Chinese and international databases, supplemented by trial registries. Preserve full strategies, dates, deduplication decisions and full-text exclusion reasons. Two researchers should independently screen and extract, resolve disagreements through a predefined process and identify multiple publications from the same trial.

Measure improvement beyond a total effective rate

A reported total effective rate may combine different scores, response thresholds and assessment days. Extract the original definitions of marked response, response and nonresponse. Where thresholds differ materially, present separate findings or narrative comparisons rather than treating identical outcome labels as identical measurements.

Time to fever resolution requires a temperature threshold, measurement site, sustained-resolution rule and information about other antipyretics. Headache outcomes need a reporting method and a distinction between initial and sustained relief. Symptom scores require scale ranges, direction, baseline values, follow-up values and variability. Check time units and distinguish standard deviations from standard errors. Missing or censored recovery times require analysis appropriate to their data structure.

Within-person improvement during a self-limiting illness differs from a treatment effect relative to a concurrent comparator. Changes should therefore be interpreted against control-group recovery. Return to usual activities, repeat consultation and patient satisfaction may add patient-relevant information. Symptom relief, shorter infection duration and fewer complications are distinct claims requiring distinct outcomes.

Make every estimate traceable

Each participant count, event count, mean and variability measure should map to a named study, page and table. Check denominators, missing outcomes and shared control groups in multi-arm trials. Example study names or summary tables without identifiable extraction sources belong in a verification log, outside a formal efficacy estimate. This article therefore omits unverified numerical summaries rather than presenting them as findings.

Choose effect measures by outcome type. Model choice should follow the question and assumptions, rather than an automatic switch based on an I-squared threshold or heterogeneity test. Clinically incompatible studies may require separate or narrative synthesis. Cochrane Handbook: analysis and meta-analysis.

For this project, prespecified comparisons can distinguish monotherapy from add-on treatment, comparator categories and illness stages. Sensitivity checks can examine high-risk studies, missing-data assumptions and unusual regimens. Their purpose is robustness, not selection of the most favorable estimate. Certainty judgments should be outcome-specific, with explicit reasons. Statistical significance should be interpreted alongside effect size, precision and clinical importance.

Put medication safety into its clinical context

Extract gastrointestinal symptoms, drowsiness and other reported events, together with withdrawals. Distinguish actively solicited symptoms, laboratory surveillance and spontaneous reporting. A short, small study with no recorded serious event provides a different safety observation from extended systematic monitoring. Reporting should preserve that distinction, including follow-up length and ascertainment intensity.

Ingredient reconciliation is particularly relevant to combination cold medicines. For acetaminophen-containing products, FDA emphasizes checking prescription and nonprescription labels, avoiding duplicate exposure and recognizing overdose-related liver injury. This is ingredient-level safety guidance, not direct efficacy evidence for Ganmaoling granules. The ingredients, population restrictions and instructions for a particular product require confirmation from its current label. FDA: acetaminophen safety information.

A collaborative QSevidence workflow

  1. Frame separate retrieval questions for the product, population, comparator, symptoms and harms.
  2. Compare candidate studies for diagnostic, intervention and outcome differences requiring review.
  3. Organize findings by applicability and evidence role: product information, direct clinical research or methodological guidance.
  4. Trace key claims to their sources for physician, pharmacist and statistical review.

Medication rounds, postgraduate projects and journal clubs can use this process to develop a product checklist, outcome dictionary and evidence-query log. Workflow evaluation can examine source locatability, agreement between independent extractors and documented corrections. These are process measures, separate from demonstrating improved patient outcomes. Professional teams use the checked evidence, actual data and clinical context to form their conclusions.

Frequently asked questions

How can QSevidence support a Ganmaoling evidence search?

QSevidence supports questions organized around drug names, formulations, indications and comparators. Researchers then verify database coverage, complete search strategies and candidate full texts to establish a reproducible starting point.

How can QSevidence help compare efficacy outcomes?

QSevidence can assist comparison of definitions and sources for response rates, symptom scores and recovery times. Clinical and statistical reviewers use primary data, measurement meaning and bias assessment to determine suitable synthesis.

How can QSevidence support medication-safety discussions?

QSevidence supports organization of label references, ingredient-related cautions and trial adverse-event reports. Pharmacists review these alongside the exact product, concurrent medicines and patient circumstances.

How should a QSevidence-supported workflow be evaluated?

Assess whether key claims have locatable sources, product details agree, bilingual facts align and revisions remain traceable. QSevidence supports evidence organization; qualified teams develop the final interpretation using verified data and methodological review.

Source roles and research notice

CDC supports illness definition; manufacturer information provides product-identification leads; FDA supplies ingredient-level safety guidance; and the Cochrane Handbook supports statistical-method checking. These sources do not establish that this project has completed a randomized-trial meta-analysis. This article concerns research and evidence workflows. Individual medication decisions should be guided by a physician or pharmacist using the applicable label and patient context.